<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05083468</url>
  </required_header>
  <id_info>
    <org_study_id>SR750-101</org_study_id>
    <nct_id>NCT05083468</nct_id>
  </id_info>
  <brief_title>The Safety, Tolerability, and Pharmacokinetics (PK) of SR750 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SR750 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SIMR (Australia) Biotech Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai SIMR Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, tolerability, and PK of SR750 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blinded, placebo-controlled, 2-part Phase I study to&#xD;
      evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending&#xD;
      doses of SR750 in healthy volunteers. This study includes 2 parts:&#xD;
&#xD;
      Part A is a double-blind, randomized, placebo-controlled, single-dose escalation study of&#xD;
      SR750 in healthy volunteers.&#xD;
&#xD;
      Part B is a double-blind, randomized, placebo-controlled, repeated-dose escalation study of&#xD;
      SR750 in healthy volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The frequency and severity of AEs in healthy volunteers administrated with single and repeated oral doses of SR750</measure>
    <time_frame>Up to Day15 for the safety follow up since Day1</time_frame>
    <description>AE: adverse event</description>
  </primary_outcome>
  <other_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to Day 10</time_frame>
    <description>Maximum observed concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to Day 10</time_frame>
    <description>Time of peak plasma concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Ctrough</measure>
    <time_frame>Up to Day 10</time_frame>
    <description>Trough concentrations, part B only.</description>
  </other_outcome>
  <other_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Up to Day 10</time_frame>
    <description>Area under the concentration-time curve from 0 to time of last quantifiable concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>Up to Day 10</time_frame>
    <description>Area under the concentration-time curve from 0 to infinity</description>
  </other_outcome>
  <other_outcome>
    <measure>t1/2</measure>
    <time_frame>Up to Day 10</time_frame>
    <description>Apparent terminal elimination half-life</description>
  </other_outcome>
  <other_outcome>
    <measure>Ae</measure>
    <time_frame>Up to Day 3, cohort 3 in part A only.</time_frame>
    <description>Cumulative amount of unchanged drug excreted in urine</description>
  </other_outcome>
  <other_outcome>
    <measure>CLr</measure>
    <time_frame>Up to Day 3, cohort 3 in part A only.</time_frame>
    <description>Renal clearance</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>SR750 tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending single and multiple doses of SR750 tablets orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ascending single and multiple doses of matching placebo orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR750 tablet</intervention_name>
    <description>The volunteers will be orally administrated by single or multiple dose of SR750 tablet with 240 mL water.</description>
    <arm_group_label>SR750 tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>The volunteers will be orally administrated by single or multiple dose of matching placebo with 240 mL water.</description>
    <arm_group_label>matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy volunteers will be included in the study if they satisfy all the following&#xD;
        criteria:&#xD;
&#xD;
          1. Must have given written informed consent before any study-related activities are&#xD;
             carried out and must be able to understand the full nature and purpose of the trial,&#xD;
             including possible risks and adverse effects.&#xD;
&#xD;
          2. Adult males and females, 18 to 55 years of age (inclusive) at Screening.&#xD;
&#xD;
          3. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2, with a body weight ≥ 50 kg for males or&#xD;
             ≥ 45 kg for females at screening.&#xD;
&#xD;
          4. Use of tobacco or nicotine-containing products:&#xD;
&#xD;
               1. Have less than 10 tobacco or nicotine-containing products (including tobacco,&#xD;
                  e-cigarettes) per week in the last 3 months prior to dosing; abstain from smoking&#xD;
                  from 7 days prior to dosing until the final follow-up visit;&#xD;
&#xD;
               2. Have not used any marijuana in the 3 months prior to screening until the end of&#xD;
                  study.&#xD;
&#xD;
          5. Medically healthy without clinically significant abnormalities at the screening visit,&#xD;
             at check-in on Day -1, and pre-dose on Day 1, including:&#xD;
&#xD;
               1. Physical examination without any clinically relevant findings;&#xD;
&#xD;
               2. Systolic blood pressure in the range of 90 to 140 mmHg (inclusive) and diastolic&#xD;
                  blood pressure in the range of 40 to 90 mmHg (inclusive) after 5 minutes in&#xD;
                  supine position;&#xD;
&#xD;
               3. Pulse rate in the range of 60 to 100 bpm, inclusive (40-60 bpm [inclusive] may be&#xD;
                  considered acceptable for athletes or volunteers without clinical significance at&#xD;
                  the discretion of the PI or designee) after 5 minutes rest in supine position;&#xD;
&#xD;
               4. Body temperature (tympanic), between 35.5°C and 37.5°C (inclusive);&#xD;
&#xD;
               5. No clinically significant findings in serum chemistry, haematology, coagulation,&#xD;
                  and urinalysis tests as judged by the Investigator.&#xD;
&#xD;
          6. Conventional 12-lead Electrocardiogram (ECG) recording in triplicate (the mean of&#xD;
             triplicate measurements will be used to determine eligibility at the screening visit,&#xD;
             on Day 1 and pre-dose on Day 1) consistent with normal cardiac conduction and&#xD;
             function, including:&#xD;
&#xD;
               1. T interval corrected using the Fridericia method (QTcF) ≤ 450 msec for males, and&#xD;
                  ≤ 470 msec for females;&#xD;
&#xD;
               2. QRS (wave group of Q, R and S in ECG) duration of ≤ 120 msec;&#xD;
&#xD;
               3. Electrocardiogram morphology consistent with healthy cardiac ventricular&#xD;
                  conduction and normal rhythm, and with measurement of the QT interval;&#xD;
&#xD;
               4. No family history of short or long QT syndrome, or sudden cardiac death;&#xD;
&#xD;
               5. No history of torsade de pointes or a known arrhythmia.&#xD;
&#xD;
          7. Healthy female volunteers must:&#xD;
&#xD;
             a) Of non-childbearing potential, defined as: i. Pre-menopausal females with a&#xD;
             documented tubal ligation, tubal occlusion procedure followed by a hysterosalpingogram&#xD;
             that confirmed bilateral tubal occlusion, bilateral salpingectomy, hysterectomy,&#xD;
             bilateral oophorectomy, or other documented medical conditions which cause infertility&#xD;
             and are considered to be of non-childbearing potential; Note: &quot;documented&quot; refers to&#xD;
             the outcome of the Investigator's/designee's review of the healthy volunteer's medical&#xD;
             history for study eligibility, as obtained via a verbal interview with the healthy&#xD;
             volunteer or from the healthy volunteer's medical records).&#xD;
&#xD;
             ii. Postmenopausal, defined as a minimum of 12 months of spontaneous amenorrhea (in&#xD;
             questionable cases a blood sample with follicle stimulating hormone [FSH] &gt;40 Million&#xD;
             International Units (mIU)/mL is confirmatory).&#xD;
&#xD;
             b) If of childbearing potential, must have a negative pregnancy test at the screening&#xD;
             visit (blood test) and before the first study drug administration (Day -1 urine test).&#xD;
             They must agree not to attempt to become pregnant, must not be breastfeeding, must not&#xD;
             donate ova from signing the consent form until at least 30 days after the last does of&#xD;
             study drug, and must agree to: i. Use 2 forms of highly effective contraceptive method&#xD;
             at least 2 weeks prior to screening, between signing consent, during the study, and at&#xD;
             least 30 days after the last dose of study therapy, OR ii. Use at least one highly&#xD;
             effective contraceptive method, plus an additional barrier-method of contraception at&#xD;
             least 2 weeks prior to screening, between signing the consent, during the study, and&#xD;
             at least 30 days after the last dose of study drug. Acceptable barrier methods&#xD;
             include: female diaphragm condom usage for male partner, OR iii. True abstinence&#xD;
             condition at least 2 weeks prior to screening, between signing consent, during the&#xD;
             study, and at least 30 days after the last dose of study therapy.&#xD;
&#xD;
             c) Women of childbearing potential (WOCBP) with solely same sex partners (abstinence&#xD;
             from penile-vaginal intercourse) are eligible when this is their preferred and usual&#xD;
             lifestyle.&#xD;
&#xD;
          8. Male healthy volunteers, if not surgically sterilised (defined as performed at least 3&#xD;
             months prior to the first dose which could be confirmed by the documentation or verbal&#xD;
             interview), must be willing not to donate sperm and, if engaging in sexual intercourse&#xD;
             with a female partner who could become pregnant, must be willing to use a condom in&#xD;
             addition to having the female partner use a highly effective contraceptive method from&#xD;
             signing the consent form until at least 90 days after the last dose of study drug. If&#xD;
             engaging in sexual intercourse with a pregnant partner, must be willing to use a&#xD;
             barrier-method of contraception. Male healthy volunteers with same-sex partner&#xD;
             (abstinence from penile-vaginal intercourse) and male healthy volunteers who are true&#xD;
             abstinence are eligible when this is their preferred and usual lifestyle.&#xD;
&#xD;
          9. Male participants must be willing to use a condom if engaging in sexual intercourse&#xD;
             with a same sex partner from signing the consent form until study exit.&#xD;
&#xD;
         10. Have suitable venous access for blood sampling.&#xD;
&#xD;
         11. Be willing and able to comply with all study assessments and adhere to the protocol&#xD;
             schedule and restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Volunteers will be excluded from the study if there is evidence of any of the following:&#xD;
&#xD;
          1. History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             hematological, gastrointestinal, endocrine, immunologic, dermatologic or significant&#xD;
             neurological or psychiatric disease (including history of epilepsy or seizures),&#xD;
             including any acute illness or major surgery within the past 3 months determined by&#xD;
             the Investigator to be clinically relevant.&#xD;
&#xD;
          2. Current infection that requires antibiotic, antifungal, antiparasitic or antiviral&#xD;
             medications.&#xD;
&#xD;
          3. Any history of malignant disease in the last 10 years (excludes completely treated&#xD;
             cutaneous squamous cell or basal cell carcinoma).&#xD;
&#xD;
          4. Presence of clinically relevant immunosuppression from, but not limited to,&#xD;
             immunodeficiency conditions such as common variable hypogammaglobulinemia.&#xD;
&#xD;
          5. Use of or having plans to use systemic immunosuppressive (e.g., corticosteroids,&#xD;
             methotrexate, azathioprine, cyclosporine) or immunomodulating medications (e.g.,&#xD;
             interferon, with the exception of topical steroid creams) during the study or within 3&#xD;
             months prior to the first study drug administration.&#xD;
&#xD;
          6. Liver function test results (i.e., aspartate aminotransferase [AST], alanine&#xD;
             aminotransferase [ALT], and gamma glutamyl transferase [GGT]) and bilirubin (total,&#xD;
             conjugated and unconjugated) elevated more than 1.2-fold above the upper limit of&#xD;
             normal (ULN).&#xD;
&#xD;
          7. Positive test results for active human immunodeficiency virus (HIV-1 and HIV-2),&#xD;
             hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies at the&#xD;
             screening visit.&#xD;
&#xD;
          8. Presence or having sequelae of gastrointestinal, liver (including Gilbert's syndrome),&#xD;
             kidney, or other conditions known to interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of drugs.&#xD;
&#xD;
          9. Estimated creatinine clearance (CrCl) &lt; 80 mL/min using the Cockcroft-Gault formula or&#xD;
             serum creatinine more than 1.5-fold above the ULN.&#xD;
&#xD;
         10. Regular use of substance abuse or alcohol abuse within 3 months prior to Screening,&#xD;
             where &quot;regular&quot; is defined as &gt;21 units of alcohol per week for males and &gt;14 units of&#xD;
             alcohol per week for females. One unit is equivalent to 8 g of alcohol: a half-pint&#xD;
             (~285 mL) of beer, 1 glass (125 mL) of wine or 1 measure (25 mL) of spirits.&#xD;
&#xD;
         11. Positive drug or alcohol test results at the screening visit or at check-in (Day -1)&#xD;
             (may be repeated once, if a positive test was recorded in the first instance, at the&#xD;
             discretion of the PI or designee).&#xD;
&#xD;
         12. Use of any systemically absorbed prescription or over-the-counter medication&#xD;
             (including herbal products, diet aids, and hormone supplements) within 10 days or 5 ×&#xD;
             half-lives of the medication (whichever is longer) prior to the first study drug&#xD;
             administration, except occasional use of paracetamol (up to a maximum of 2000 mg per&#xD;
             day of paracetamol and per local or national labelling) or hormonal contraceptives.&#xD;
&#xD;
         13. History of demonstrated clinically significant (required intervention, e.g., emergency&#xD;
             room visit, epinephrine administration) allergic reactions (e.g., food, drug, or&#xD;
             atopic reactions, asthmatic episodes) which, in the opinion of the Investigator, would&#xD;
             increase the risk of having allergic reactions associated with investigational product&#xD;
             administration.&#xD;
&#xD;
         14. Known hypersensitivity to any of the study drug ingredients.&#xD;
&#xD;
         15. Use of any vaccinations within 7 days prior to the first study drug administration, or&#xD;
             plan to use any vaccinations within 2 weeks after the last dose.&#xD;
&#xD;
         16. Donation of blood or plasma within 30 days prior to first study drug administration,&#xD;
             or loss of whole blood of more than 500 mL within 30 days prior to randomization, or&#xD;
             receipt of a blood transfusion within 1 year of first study drug administration.&#xD;
&#xD;
         17. The healthy volunteer has participated in a clinical trial and has received an&#xD;
             investigational product within the following time period prior to the first dosing day&#xD;
             in the current study: 30 days, 5 half-lives or twice the duration of the biological&#xD;
             effect of the investigational product (whichever is longer).&#xD;
&#xD;
         18. Any other condition or prior therapy that in the opinion of the Investigator would&#xD;
             make the volunteer unsuitable for this study, including inability to cooperate fully&#xD;
             with the requirements of the study protocol or likelihood of noncompliance with any&#xD;
             study requirements.&#xD;
&#xD;
         19. Is an employee of an Investigator or Sponsor or an immediate relative of an&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cameron Johnson</last_name>
    <role>Study Director</role>
    <affiliation>Nucleus Network Pty Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tina Zhao</last_name>
    <phone>+862161161537</phone>
    <email>contact@simrbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nucleus Network Pty Ltd</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cameron Johnson</last_name>
      <phone>+61 3 9076 8906</phone>
      <email>c.johnson@nucleusnetwork.com.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

